Evidence map›Paper›PMID 42265107›Full record

ArticleNature communications2026

Diverse germline-targeting HIV Env immunogens select for distinct mutations in the same knock-in mice B cell receptors.

Parul Agrawal, Junli Feng, Latha Kallur Siddaramaiah, Arineh Khechaduri, Kelsey R Salladay, Karli Hinton, Madison Means, Julianna A Rose, Luziana Cohen, Ming Tian and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Parul AgrawalVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pagrawal@fredhutch.org.ORCID 0000-0002-2968-3197
Junli FengVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Latha Kallur SiddaramaiahVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Arineh KhechaduriVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kelsey R SalladayVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Karli HintonVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-0372-3178
Madison MeansVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Julianna A RoseVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Luziana CohenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0009-0009-9052-5428
Ming TianBoston Children's Hospital, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA, USA.
Sabyasachi BabooDepartment of Integrated Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-4547-5160
Jolene K DiedrichDepartment of Integrated Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Todd ReeseVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Derin KaraVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0009-0009-5714-1545
John R YatesDepartment of Integrated Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-5267-1672
James C PaulsonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-4589-5322
Frederick W AltBoston Children's Hospital, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0002-0583-1271
Marie PanceraVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0001-9217-6270
Leonidas StamatatosVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. lstamata@fredhutch.org.ORCID 0000-0002-1106-7097

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Recombinant HIV-1 Env glycoprotein immunogens and antibodies production and structural characterizationP01AI138212 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STAMATATOS, LEONIDAS · 2019 to 2023
$9.2M
Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunizationR01AI177095 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Leonidas Stamatatos · 2024 to 2026
$2.1M
NIAID NIH HHS P01 AI138212NIAID NIH HHS R01 AI177095NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

VRC01-class HIV broadly neutralizing antibodies have been isolated from people living with HIV. Their unmutated (germline) forms do not bind Env and do not neutralize HIV. They acquire their broadly neutralizing potentials through the accumulation of specific somatic mutations. Here, we identify key modifications that allow Env-derived proteins from diverse HIV clades to effectively engage germline VRC01-class B cell receptors (BCRs) expressed by naive B cells. Noticeably, these germline-targeting Env proteins interact with VRC01-class BCRs differently depending on the specific Env background. When used as immunogens in a knock-in mouse model, all germline-targeting Envs successfully activate VRC01-class B cells. However, the resulting BCRs accumulate distinct mutations at key positions. Thus, while the same BCRs are initially activated, they follow different maturation pathways depending on the immunogen used. These findings have important implications not only for HIV vaccine design efforts but also for other immunogens aiming to direct specific BCR maturation pathways.

Indexed as

env Gene Products, Human Immunodeficiency VirusHIV-1Receptors, Antigen, B-CellAIDS VaccinesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingB-LymphocytesBroadly Neutralizing AntibodiesFemaleGene Knock-In TechniquesHIV AntibodiesHIV InfectionsHumansMiceMutationAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesReceptors, Antigen, B-CellVRC01 monoclonal antibody

Identifiers

PMID42265107
PMCPMC13402730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.